Vertical: CNMBase Year: 2025
Market Size (2025)
$225.93M
Projected (2032)
$346.51M
CAGR (2022–2032)
7.0%
Key Players
10+
Market Overview
The global bioresorbable polymers market was valued at USD 225.93 Million in 2025 and is projected to reach USD 346.51 Million by 2032, expanding at a compound annual growth rate (CAGR) of 6.18% over 2026–2032. The market has grown steadily from USD 176.55 Million in 2022, and is expected to reach USD 241.82 Million in 2026, the first year of the forecast period. Over 2025–2032 the market is expected to add USD 120.58 Million in absolute value.
Bioresorbable polymers are synthetic, medical-grade polyesters and related materials that degrade in the body through hydrolysis and are metabolised or excreted, removing the need for a second surgery to retrieve an implant and allowing controlled release of active pharmaceutical ingredients. Demand is anchored in three end-use areas: orthopedic and sports-medicine fixation devices, controlled-release drug delivery systems such as long-acting injectable microspheres and implants, and absorbable sutures and other soft-tissue devices. Growth is supported by ageing populations, rising surgical volumes, the expansion of long-acting injectable drug pipelines and the steady substitution of permanent metallic and non-absorbable devices in selected indications.
Key Findings
Polymer type: PLGA was the largest polymer type in 2025 at USD 79.08 Million (35.00% share), while PCL is the fastest-growing polymer type with a CAGR of 8.61% over 2026–2032.
Application: Orthopedic Devices and Sutures & Others jointly led the application segmentation in 2025, each valued at USD 79.08 Million and each accounting for 35.00% of the market. Drug Delivery is the fastest-growing application with a CAGR of 8.04%, and is projected to become the largest application by 2032 at USD 117.16 Million.
Region: North America was the leading region in 2025 with USD 90.37 Million (40.00% share). Asia Pacific is the fastest-growing region with a CAGR of 8.84%, rising from USD 56.48 Million in 2025 to USD 102.77 Million in 2032.
Country: The U.S. was the leading country market in 2025 at USD 76.82 Million, equivalent to 34.00% of global revenue. India is the fastest-growing country, with a CAGR of 11.90% over 2026–2032.
Segmentation Summary
By polymer type, the market is segmented into PLGA, PLA, PCL and Others. PLGA accounted for 35.00% of 2025 revenue, reflecting its central role in drug delivery microspheres and absorbable devices whose degradation rate can be tuned by varying the lactide-to-glycolide ratio. PLA held 30.00%, supported by its use in orthopedic screws, pins, anchors and plates. PCL, with a 15.00% share, is the fastest-growing polymer type (8.61% CAGR) owing to its use in long-term implants, tissue-engineering scaffolds, aesthetic injectables and 3D-printed devices. The Others segment, covering polymers such as polyglycolic acid, polydioxanone and specialty copolymers, represented 20.00%.
By application, the market is segmented into Orthopedic Devices, Drug Delivery and Sutures & Others. Orthopedic Devices and Sutures & Others each held 35.00% in 2025, while Drug Delivery accounted for 30.00%. Drug Delivery is expected to grow at 8.04%, well above the market average, and to reach USD 117.16 Million by 2032.
Competitive Landscape Summary
The market is moderately consolidated. Evonik Industries (RESOMER and LACTEL) and Corbion (PURASORB) are the established leaders in GMP-grade lactide, glycolide and caprolactone polymers, supplying both implantable devices and long-acting injectables from production sites in Europe and the United States. Ashland (Viatel) and Seqens (EXPANSORB) are strengthening their positions through capacity investments and new high-purity and high-molecular-weight grades. Specialists such as DSM Biomedical, Poly-Med, Foster (a GEON company), Zeus (Absorv), BMG Incorporated and Jinan Daigang Biomaterial compete in specific niches, including resorbable composites, fibres and textiles, compounding, precision extrusions and regional supply. Since 2022, competitive activity has focused on GMP capacity expansion, high-purity and customised grades, formats for 3D printing, distribution partnerships and private-equity acquisitions of specialist processors.
Challenges and Opportunities
The principal challenges are the cost and duration of qualifying medical-grade polymers for implantable devices and parenteral drug products, the stringent and evolving regulatory environment (notably the EU Medical Device Regulation and FDA expectations for absorbable implants), and technical constraints such as lower mechanical strength than metals and the need to manage acidic degradation by-products. The withdrawal of the first-generation fully bioresorbable coronary scaffold from the market in 2017 continues to shape cautious clinical adoption in load-bearing and vascular indications.
Opportunities centre on long-acting injectable formulations for chronic diseases, next-generation resorbable scaffolds for peripheral and cardiovascular use, additive manufacturing of patient-specific implants and tissue-engineering scaffolds, aesthetic injectables based on PLLA and PCL, and capacity localisation in Asia Pacific, where the market is forecast to grow at 8.84%.
Future Outlook
The market is expected to expand from USD 241.82 Million in 2026 to USD 346.51 Million in 2032. The mix will shift gradually towards drug delivery and towards PCL and PLGA grades, while the regional balance will move towards Asia Pacific, whose share will rise as China and India expand domestic device and pharmaceutical manufacturing. Suppliers that combine GMP-grade polymer production with formulation, processing and regulatory support services are expected to capture a disproportionate share of new programmes.
The Bioresorbable Polymers Market market is projected to grow at a CAGR of 7.0% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Bioresorbable polymers are synthetic polymers, predominantly aliphatic polyesters, that are designed to degrade in vivo, mainly by hydrolytic cleavage of ester bonds, into low-molecular-weight fragments and monomers that are metabolised or eliminated by natural pathways. In this study, the market comprises medical-grade and GMP-grade polymer resins, copolymers and polymer-based intermediates (granules, powders, fibres and extrusion feedstock) supplied for use in medical devices and pharmaceutical products. The principal chemistries are poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA, including PLLA and PDLLA), polycaprolactone (PCL), and other bioresorbable polymers such as polyglycolic acid (PGA), polydioxanone (PDO), poly(trimethylene carbonate) and specialty copolymers.
Included: sales of bioresorbable polymer materials to device manufacturers, pharmaceutical companies, contract development and manufacturing organisations and research institutions for orthopedic devices, drug delivery systems, sutures and other medical applications. Excluded: commodity and packaging-grade biodegradable plastics (for example PLA for films, fibres and consumer goods), natural biopolymers such as collagen, chitosan and hyaluronic acid, resorbable metals such as magnesium alloys, and the value added by finished medical devices or drug products beyond the polymer itself.
Scope of the Study
Segmentation by Polymer Type: PLGA, PLA, PCL, Others.
Segmentation by Application: Orthopedic Devices, Drug Delivery, Sutures & Others.
Regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, with country-level analysis of U.S., Canada, Mexico; Germany, U.K., France, Italy, Spain, Rest of Europe; China, India, Japan, Rest of Asia Pacific; Brazil, Argentina, Rest of Latin America; UAE, Saudi Arabia, South Africa, Rest of MEA.
Timeline: historic years 2022, 2023 and 2024; base year 2025; forecast years 2026–2032; CAGR stated for 2026–2032.
Unit: all market values are presented in USD Million.
Research Objectives
To estimate the size of the global bioresorbable polymers market in USD Million for the historic years 2022–2024 and the base year 2025, and to forecast it for 2026–2032.
To analyse the market by polymer type (PLGA, PLA, PCL and Others) and quantify the revenue contribution and growth of each polymer chemistry.
To analyse the market by application (Orthopedic Devices, Drug Delivery and Sutures & Others) and assess how clinical practice and drug-pipeline trends shape demand.
To assess the market across five regions and their key countries, identifying the fastest-growing geographies for polymer suppliers.
To identify drivers, restraints, opportunities and trends affecting the adoption of bioresorbable polymers in medical devices and pharmaceuticals.
To evaluate the value chain, competitive intensity (Porter's Five Forces), regulatory landscape and PESTEL factors specific to medical-grade bioresorbable polymers.
To profile the competitive environment, positioning of leading polymer suppliers and key strategic developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage process: definition of scope and segmentation; collection of secondary data on polymer production, medical device and pharmaceutical demand; primary validation with industry participants; construction of a market model using top-down and bottom-up approaches; triangulation of the resulting estimates; and forecasting based on quantified demand drivers. Each stage was reviewed against the others so that segment, regional and country totals reconcile to the global market value in every year.
Secondary Research
Industry associations: publications and statistics from bodies such as AdvaMed, MedTech Europe, the Society for Biomaterials, the European Society for Biomaterials and national orthopedic and surgical societies.
Government and regulatory bodies: device clearance and approval databases of the U.S. FDA (510(k), PMA and De Novo), EU MDR documentation and notified-body information, PMDA (Japan), NMPA (China), CDSCO (India) and ANVISA (Brazil); public health and procedure statistics from national health agencies and the World Health Organization.
Company filings: annual reports, investor presentations, sustainability reports and press releases of polymer producers, medical device manufacturers and pharmaceutical companies developing long-acting injectables.
Trade and scientific journals: peer-reviewed literature on biomaterials, controlled release and orthopedic outcomes, and trade publications covering medical plastics and pharmaceutical excipients.
Paid databases: company financial databases, clinical-trial registries, patent databases and trade-statistics services covering lactide, glycolide, caprolactone and related polymer flows.
Primary Research
Primary research was used to validate secondary findings, fill information gaps and test the assumptions of the market model. Discussions were held with participants on both the supply side and the demand side of the market.
Supply side: product managers, business development leaders and technical service specialists at bioresorbable polymer producers, monomer suppliers, custom polymer synthesis firms and contract processors (extrusion, fibre spinning, microsphere manufacturing).
Demand side: R&D, sourcing and regulatory personnel at orthopedic and wound-closure device manufacturers, formulation scientists at pharmaceutical companies and CDMOs, and clinicians and procurement staff at hospitals.
Objectives: to validate pricing and volume assumptions by polymer grade, confirm application splits, understand qualification timelines and switching behaviour, and assess the outlook for new indications and regions.
Market Size Estimation
Top-down approach: the addressable value of relevant medical device and drug delivery markets was identified and the polymer content of each was estimated using typical polymer weight per device or dose, polymer cost-in-use and penetration rates of bioresorbable versus permanent materials. Bottom-up approach: revenues of leading polymer suppliers attributable to medical-grade bioresorbable polymers were estimated from company disclosures, capacity data and primary interviews, and aggregated by polymer type and region, with an allowance for smaller and regional producers.
Data triangulation: results from both approaches were compared at the global, regional and segment levels. Where differences arose, the underlying assumptions (pricing, polymer loading, penetration and supplier coverage) were revisited and reconciled through further primary validation, so that the final estimates are consistent across all dimensions.
Forecasting Methodology
Forecasts were developed for each region, country and segment and then aggregated. Factors considered include demographic change and the prevalence of musculoskeletal and chronic diseases, surgical procedure volumes, the pipeline and launch schedule of long-acting injectable and implantable drug products, regulatory timelines, healthcare expenditure growth, polymer pricing trends, supplier capacity additions and the substitution of permanent materials. Historic growth rates were used as a baseline and adjusted with weighted driver and restraint scores; the resulting forecasts were reviewed with industry participants.
Base Year, Forecast Period and Currency
Base year: 2025
Historic period: 2022–2024
Forecast period: 2026–2032 (CAGR stated for 2026–2032)
Currency: USD Million, at constant exchange rates of the base year
Assumptions and Limitations
The market is valued at the level of polymer material sales and excludes the value of finished devices and drug products.
Macroeconomic conditions are assumed to remain broadly stable, with no major disruption to healthcare spending or supply chains over the forecast period.
Regulatory frameworks are assumed to evolve along currently announced timelines, including the EU MDR transition deadlines.
Revenue of diversified suppliers attributable to bioresorbable polymers is not reported separately and has been estimated; actual figures may differ.
Country-level estimates for smaller markets rely on a narrower base of data and are subject to a wider margin of uncertainty.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The bioresorbable polymers market is moderately consolidated. A small group of global producers with GMP manufacturing, regulatory master files and decades of clinical history supply the majority of medical-grade lactide, glycolide and caprolactone polymers, while a wider group of specialist polymer makers, compounders, extruders and regional producers serve particular applications or geographies. Competition is driven less by price than by consistency of quality, breadth of grades, the ability to develop custom polymers, regulatory documentation and technical support during customer development programmes. Once a polymer grade is specified in an approved device or drug product, changing supplier requires additional testing and regulatory filings, so incumbent suppliers benefit from long customer relationships.
Competitive activity since 2022 has centred on capacity expansions in Europe and the United States, launches of high-purity, high-molecular-weight and 3D-printing grades, distribution partnerships to widen market reach, and acquisitions of specialist processors by private-equity-backed groups. Price competition is stronger in research-grade polymers and in China and India, where domestic producers are expanding.
Key Player Positioning
Leaders: Evonik Industries and Corbion have the broadest portfolios of GMP bioresorbable polymers, long clinical and commercial track records, production in both Europe and the United States, and supply relationships with major device and pharmaceutical companies across implantable devices and long-acting injectables.
Challengers: Ashland and Seqens are investing in capacity and differentiated grades. Ashland's Viatel business, based in Mullingar, Ireland, has added Ultrapure and high-molecular-weight grades, while Seqens offers EXPANSORB catalogue and custom polymers for long-acting injectables backed by Drug Master Files.
Niche players: DSM Biomedical focuses on specialised biomaterials, resorbable composites and contract manufacturing; Poly-Med on proprietary absorbable polymer families and fibre, textile and electrospun products; Foster on compounding of bioresorbable resins with ceramics and additives; Zeus on precision bioabsorbable extrusions for scaffolds and devices; BMG Incorporated on bioabsorbable polymers and absorbable devices in Japan; and Jinan Daigang Biomaterial on a broad catalogue of monomers and polymers for the Chinese research and medical market.
Competitor Dashboard
The dashboard below rates each profiled company on four dimensions: breadth of bioresorbable product portfolio, regional presence, strategic alliances and industry experience.
Threat of New Entrants: Low
GMP facilities, validated analytical methods and regulatory master files require substantial investment and several years to establish.
Customers face long qualification cycles and regulatory change notifications, so they rarely switch to unproven suppliers.
Regional producers in China and India are entering at the lower end, but mostly for domestic customers.
Bargaining Power of Suppliers: Low
Leading polymer producers are often integrated into monomer production or source lactide and glycolide from several suppliers.
Monomer cost is a small part of the value of medical-grade polymers, limiting supplier leverage.
Bargaining Power of Buyers: Medium
Large orthopedic, wound-closure and pharmaceutical companies negotiate long-term contracts and can dual-source.
High switching costs once a grade is specified in an approved product limit buyers' ability to change suppliers.
Smaller device start-ups and generic developers have little negotiating power.
Threat of Substitutes: Medium
Titanium, stainless steel and PEEK remain the standard for load-bearing fixation.
Natural polymers (collagen, hyaluronic acid) and resorbable magnesium alloys compete in selected indications.
Non-absorbable sutures remain preferred where permanent support is needed.
Competitive Rivalry: Medium
The market is moderately consolidated, with a small number of global suppliers holding long-standing customer relationships.
Competition is based on quality, consistency, regulatory support and breadth of grades rather than on price.
Rivalry is more price-based in generic polymer grades and in tender-driven emerging markets.
Threat of New Entrants: Low; GMP facilities, validated analytical methods and regulatory master files require substantial investment and several years to establish.
Bargaining Power of Suppliers: Low; Leading polymer producers are often integrated into monomer production or source lactide and glycolide from several suppliers.
Bargaining Power of Buyers: Medium; Large orthopedic, wound-closure and pharmaceutical companies negotiate long-term contracts and can dual-source.
Threat of Substitutes: Medium; Titanium, stainless steel and PEEK remain the standard for load-bearing fixation.
Competitive Rivalry: Medium; The market is moderately consolidated, with a small number of global suppliers holding long-standing customer relationships.
Market estimates by geography (2032)
InsightNorth America leads with $128.33M by 2032, while Asia Pacific is projected to grow fastest at a 9.5% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $72.01M | $101.47M | $128.33M | 5.9% | 37% |
| Europe | $50.88M | $70.73M | $88.22M | 5.7% | 25% |
| Asia Pacific | $41.49M | $67.63M | $102.77M | 9.5% | 30% |
| Latin America | $7.12M | $10.61M | $15.33M | 8.0% | 4% |
| Middle East & Africa | $5.06M | $8.03M | $11.86M | 8.9% | 3% |
| Total | $176.55M | $258.46M | $346.51M | 7.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$346.51M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| PLGA | $125.68M | 7.5% | 36% |
| PLA | $92.21M | 5.3% | 27% |
| Others | $67.83M | 6.7% | 20% |
| PCL | $60.78M | 9.3% | 18% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Bioresorbable Polymers Market covering market dynamics, competitive landscape, and strategic outlook.
The Bioresorbable Polymers Market market is projected to reach $346.51M by 2032, growing at 7.0% CAGR. The PLGA segment holds the largest share.
The bioresorbable polymers market is shaped by the interaction of clinical demand, pharmaceutical innovation, regulation and supply-side capability. This chapter sets out the macro and micro factors influencing growth, followed by the principal drivers, restraints, opportunities, trends and challenges. The impact scores in Table 4.1 are analyst assessments on a scale of 1 (minimal impact) to 10 (very strong impact), based on the secondary and primary research described in Chapter 3; they indicate the relative strength of each factor in each period rather than a precise quantification.
Growing Use of Long-Acting Injectable and Controlled-Release Formulations
PLGA and related polyesters are the established matrix materials for long-acting injectable microspheres, in situ forming depots and solid implants, enabling drug release over weeks to months. Marketed products such as leuprolide acetate depots for prostate cancer, risperidone microspheres for schizophrenia and exenatide extended-release for type 2 diabetes have demonstrated the clinical and commercial value of PLGA-based release systems. Pharmaceutical companies are applying the same platforms to improve adherence in chronic conditions including psychiatric disorders, opioid use disorder, hormone therapy and metabolic disease, and the expiry of patents on several first-generation depots has opened the door to complex generic versions that require equivalent polymer specifications. The U.S. FDA has issued product-specific guidance for generic PLGA-based products, which has encouraged generic developers to invest in polymer characterisation and secure long-term supply. Because each formulation is developed around a specific polymer composition, molecular weight and end-group, approved products create durable, high-value demand for qualified GMP polymer grades. These dynamics underpin the above-average growth of the Drug Delivery application and of PLGA within the polymer type segmentation.
Ageing Populations and Rising Orthopedic and Sports-Medicine Procedure Volumes
The World Health Organization estimates that the number of people aged 60 years and over will reach 2.1 billion by 2050, and musculoskeletal conditions are a leading contributor to disability worldwide. At the same time, participation in sport among younger and middle-aged adults sustains high volumes of ligament reconstruction, meniscal repair and shoulder stabilisation procedures. Bioresorbable interference screws, suture anchors, pins, tacks and plates made from PLLA, PLGA and composite polymers are widely used in these procedures because they avoid long-term implant presence, reduce stress shielding and eliminate removal operations, and because they do not interfere with post-operative MRI or CT imaging. Craniomaxillofacial and paediatric fixation is another established use, since resorbable plates do not restrict skeletal growth. Growth in ambulatory surgery centres in the United States and expanding orthopedic capacity in Asia Pacific add to procedure volumes. As device makers introduce composite resorbable devices that incorporate osteoconductive ceramics such as beta-tricalcium phosphate or hydroxyapatite, polymer demand per device and per procedure is expected to rise further.
Large and Growing Base of Surgical Procedures Using Absorbable Wound Closure
More than 300 million major surgical procedures are performed worldwide each year, and absorbable sutures made from polyglycolic acid, polyglactin (PLGA copolymer), polydioxanone and poly(glycolide-co-caprolactone) are the standard choice for many internal closures. Absorbable sutures, ligating clips, meshes and staples remove the need for removal visits, lower the risk of chronic foreign-body reactions and suit minimally invasive and robotic procedures. Antibacterial coated absorbable sutures, recommended in World Health Organization guidelines on surgical site infection prevention, have reinforced the use of absorbable materials in general, obstetric and orthopedic surgery. Expanding surgical access in emerging economies, supported by public insurance schemes and investment in hospital infrastructure, is adding substantial new volume. Because sutures and related soft-tissue devices are consumed in high volumes, this application provides a large and resilient base of polymer demand that cushions the market against cycles in individual device categories.
Supplier Investment in GMP Capacity, Custom Polymers and Services
Leading suppliers are investing in GMP capacity, new grades and customer services, which improves supply security and lowers barriers to adoption for device and drug developers. Ashland completed an expansion of its Viatel bioresorbable polymer manufacturing and R&D facility in Mullingar, Ireland, in August 2024 and has since introduced Viatel Ultrapure (October 2023) and high-molecular-weight Viatel grades (June 2025). Evonik expanded capacity for customised RESOMER powders in Darmstadt, Germany, in April 2024 and appointed IMCD as its European distributor of RESOMER polymers for implantable devices from July 2025. Seqens invested in a new cGMP polymers and lipids unit at Aramon, France, during 2023–2024, while DSM Biomedical invested in a new manufacturing facility in Exton, Pennsylvania, in 2024. Corbion's BRIGHT 2030 strategy, presented in November 2025, names the growth of its biomedical polymers business as a strategic priority. Private-equity investment in specialist processors, including EQT's acquisition of Zeus (completed in March 2024) and GEON's acquisition of Foster (January 2025), adds further capital to conversion capacity. These investments widen the range of grades available, shorten development timelines through custom synthesis and regulatory support, and help sustain market growth over the forecast period.
Next-Generation Resorbable Scaffolds and Cardiovascular Devices
After the first generation of coronary scaffolds, development has moved to thinner-strut designs and to peripheral indications. In April 2024 the U.S. FDA approved Abbott's Esprit BTK everolimus-eluting resorbable scaffold for below-the-knee arterial disease, showing that resorbable polymer scaffolds can achieve regulatory approval where long-term vessel restoration is valuable. Further programmes in peripheral, coronary and paediatric cardiovascular applications offer high-value demand for advanced PLLA and copolymer grades.
Additive Manufacturing, Regenerative Medicine and Aesthetics
PCL, PLGA and PLA are well suited to 3D printing and electrospinning of patient-specific implants, bone-void fillers and tissue-engineering scaffolds, and several printed resorbable devices have reached clinical use. In aesthetics, injectable PLLA and PCL microspheres used as collagen stimulators are a fast-growing niche. Suppliers offering printable filaments, powders and medical-grade microspheres can address these emerging, higher-margin uses.
Localisation of Device and Pharmaceutical Manufacturing in Emerging Markets
Government programmes such as India's Production Linked Incentive scheme for medical devices and China's support for domestic high-end medical devices are encouraging local manufacturing of implants, sutures and complex generics. Asia Pacific, forecast to grow at 8.84% over 2026–2032, offers opportunities for suppliers that establish local technical service, regulatory documentation and, over time, local production.
High Cost and Lengthy Qualification of Medical-Grade Polymers
Medical-grade bioresorbable polymers are produced in small batches under GMP conditions with tight control of residual monomer, catalyst residues, molecular weight distribution and moisture, and are sold at prices many times higher than industrial polymers. Device makers and pharmaceutical companies must qualify each grade through biocompatibility testing, degradation studies and stability programmes, and any later change of supplier or grade can trigger new regulatory submissions. These costs and timelines slow adoption in price-sensitive markets and discourage substitution in established products, particularly in hospital tenders and volume-based procurement programmes where permanent devices are cheaper.
Technical Limitations and Clinical Performance Concerns
Bioresorbable polymers have lower strength and stiffness than titanium or stainless steel, which restricts their use in load-bearing applications. Degradation releases acidic products that can cause local inflammatory reactions or osteolysis if degradation is too rapid, and degradation rates vary with implant geometry, sterilisation and patient factors. The commercial withdrawal of Abbott's Absorb bioresorbable vascular scaffold in 2017, following low sales and clinical data showing higher rates of adverse events than metallic drug-eluting stents, illustrated these risks and made clinicians and regulators more cautious about first-generation resorbable implants in demanding indications.
Regulatory Complexity for Absorbable Implants
Under the EU Medical Device Regulation (EU) 2017/745, many absorbable implants fall into the highest risk class and require extensive clinical evidence and notified-body review, and notified-body capacity constraints led the EU to extend MDR transition periods through Regulation (EU) 2023/607. In the United States, absorbable implants often require additional degradation and long-term safety data. These requirements raise development costs and lengthen time to market for new devices.
Challenge: Sterilisation, Stability and Supply Security
Bioresorbable polymers are sensitive to moisture, heat and radiation, which constrains sterilisation options and requires cold-chain storage in some cases. The limited number of qualified GMP producers means that supply disruptions or capacity shortfalls can affect many customers at once, prompting dual-sourcing and inventory strategies.
Challenge: Pricing Pressure in Tender-Driven Markets
Volume-based procurement for orthopedic consumables in China and tender-based purchasing in parts of Europe and Latin America put pressure on device prices, which is passed back to material suppliers and encourages qualification of lower-cost regional producers.
Trend: Custom and Functionalised Polymer Grades
Customers increasingly specify polymers by copolymer ratio, inherent viscosity, end-group chemistry and architecture (for example acid-terminated, ester-capped or PEG-block copolymers) to fine-tune release kinetics and degradation. Suppliers are responding with wider catalogues, custom synthesis and analytical services, which deepens customer relationships and raises switching costs.
Trend: Composite and Drug-Eluting Resorbable Devices
Device designs increasingly combine resorbable polymers with ceramics, antibiotics, growth factors or anti-proliferative drugs, blurring the line between device and drug and creating demand for polymers with documented compatibility with active ingredients.
The bioresorbable polymers value chain runs from monomer feedstocks through GMP polymerisation and conversion to device and pharmaceutical manufacturers and, ultimately, to hospitals and patients. Value is concentrated in the polymerisation and purification stage, where control of quality and regulatory documentation determines access to customers.
2022: Poly-Med, Inc.; Expansion; Expanded operations with a new facility in Liberty, South Carolina, adding to its sites in Anderson and Powdersville.
Jun 2022: Ashland Inc.; Expansion; Began construction of an expansion of its Viatel bioresorbable polymers manufacturing and R&D site in Mullingar, Ireland.
Jan 2023: Seqens; Expansion; Opened the Seqens Boston R&D Center in Devens, Massachusetts, focused on APIs and excipients, including custom polymers.
Mar 2023: Evonik Industries AG; Partnership; Announced a partnership with BellaSeno to commercialise 3D-printed resorbable bone scaffolds made from RESOMER polymers.
May 2023: Corbion N.V.; Product approval; FDA approved Teva and MedinCell's risperidone extended-release injectable based on the BEPO technology, which uses PEG-PLA copolymers supplied by Corbion through its CM Biomaterials joint venture with MedinCell.
Sep 2023: Zeus Company; Product launch; Launched Absorv XSE oriented bioabsorbable tubing for bioresorbable vascular scaffolds.
Oct 2023: Ashland Inc.; Product launch; Launched Viatel Ultrapure bioresorbable polymers with low residual monomer for long-acting injectables, implants and degradable devices.
Jan 2024: Seqens; Partnership; Partnered with Pleryon to develop and manufacture a custom cGMP functional polymer for an osteoarthritis therapy at its Aramon, France, site.
Feb 2024: DSM Biomedical; Expansion; Invested in a new facility in Exton, Pennsylvania, to support its specialised biomaterials manufacturing strategy.
Mar 2024: Zeus Company; Acquisition; EQT Private Equity completed its acquisition of Zeus, announced in December 2023.
Apr 2024: Evonik Industries AG; Expansion; Expanded capacity for customised RESOMER powder biomaterials in Darmstadt, Germany, using solvent-free micronisation technology.
2024: Seqens; Expansion; Completed investment of EUR 15 million in a new cGMP polymers and lipids unit at Aramon, France, supported by the France Relance programme.
Aug 2024: Ashland Inc.; Expansion; Completed the expansion of its Viatel manufacturing and R&D facility in Mullingar, Ireland, adding laboratories, clean rooms and production capacity.
Jan 2025: Foster, LLC; Acquisition; Acquired by GEON Performance Solutions, becoming GEON's platform for the medical end market.
Mar 2025: BMG Incorporated; Product approval; Received Japanese manufacturing and marketing approval for LYDEX Sealant, an absorbable tissue reinforcement material.
Jun 2025: Ashland Inc.; Product launch; Introduced high-molecular-weight Viatel bioresorbable polymer grades for medical devices, dermal fillers, tissue engineering and long-acting injectables.
Jul 2025: Evonik Industries AG; Partnership; Appointed IMCD as exclusive distributor of RESOMER polymers for implantable medical devices in Europe.
Jul 2025: Foster, LLC; Partnership; Appointed Formerra as preferred distributor of Foster medical compounds across the Americas.
Nov 2025: Corbion N.V.; Strategy; Presented its BRIGHT 2030 strategy, naming growth of the Biomedical Polymers business as a strategic priority.
Aug 2026: Seqens; Restructuring; Reached an agreement in principle on a financial restructuring under which its senior lenders will become shareholders, with completion expected by the end of 2026.
Political
Government programmes supporting domestic medical device manufacturing in China and India favour local sourcing.
Trade tensions and tariffs on medical devices and chemicals affect cross-border supply of polymers and finished devices.
Economic
Healthcare spending growth and expansion of insurance coverage increase surgical volumes in emerging economies.
Cost containment and tender-based procurement put pressure on device and material pricing.
Exchange-rate movements affect the competitiveness of European and Japanese suppliers.
Social
Ageing populations and rising rates of obesity and osteoarthritis increase demand for orthopedic procedures.
Patient preference for avoiding implant-removal surgery supports bioresorbable devices.
Growing demand for aesthetic procedures supports PLLA and PCL injectables.
Technological
Advances in polymer synthesis allow precise control of degradation and drug release.
Additive manufacturing and electrospinning enable patient-specific implants and scaffolds.
Composite and drug-eluting resorbable devices broaden clinical use.
Environmental
Lactic acid is derived from renewable feedstocks, supporting sustainability positioning.
Solvent use and energy consumption in GMP purification are under scrutiny in corporate sustainability programmes.
Legal
EU MDR and FDA requirements for absorbable implants raise evidence and documentation standards.
Patent expiry of first-generation long-acting injectables enables complex generics.
Product liability exposure encourages rigorous supplier qualification.
Profiles of 29 companies operating in the Bioresorbable Polymers Market market, including revenue, employee count, and market positioning where available.
Showing 29 of 29 companies
Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.
Company Headquarters: Orangeburg, United States Founded: 1966 Workforce: ~ 1,700 Company Working: Zeus Company Inc is a leading innovative polymer solution company. The company creates and manufactures a wide range of products that are essential for daily living. It offers comprehensive solutions with a worldwide footprint, local resources, assistance for design and application development, and in-depth technical expertise to develop ground-breaking solutions. Additionally, the company is a leading producer of insulating materials including PEEK, ECTFE, bioresorbable polymers, and others. The product portfolio of the company includes biomaterials, reinforced optical fiber, extruded tubing, heat shrinkable tubing, insulated wire, monofilament and drawn fiber, polyimide family, and others. It offers PEEK-coated magnet wire for various applications in automotive industries and others. It has 11 world-class manufacturing facilities and serves in more than 180 countries across the Americas, Europe, Asia-Pacific, Middle East, and Africa.
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix | Revenue type | Characterisation | Evidence | |---|---|---| | Product sales | Dominant (estimated well above 90% of revenue; exact split not publicly disclosed) | Manufactured coatings, sealants, admixtures and similar products sold through retail, distribution and direct channels | | Installation and services | Material within CPG and PCG; not separately disclosed | WTI/WTC roofing services, turnkey general contracting, TremCare maintenance programs, Stonhard installed flooring, Legend Brands/RoofTec restoration services, Pure Air Control Services | | Warranty and extended programs | Embedded in pricing; generates deferred revenue | Current unearned revenue USD 75.3M and long-term unearned revenue USD 92.4M at FY2026 (standardized balance sheet) | | Licensing and royalties | Minor | The 10-K notes license fees and royalty income from numerous international license agreements, plus equity-method joint ventures | | Subscription | None identified | — | RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Customer types and end markets | End market | Segment exposure | Representative brands | |---|---|---| | Commercial / institutional building envelope (roofing, walls, waterproofing, sealants) | CPG | Tremco, Dryvit, Nudura, illbruck, Kalzip, Volteco | | Concrete, cement and infrastructure | CPG, PCG | Euclid, Toxement, Viapol, Prime Resins, Fibrecrete | | Industrial maintenance, oil and gas, petrochemical, power, data centres | PCG | Carboline, Stonhard, Fibergrate, Nullifire | | Food and pharma | PCG | Mantrose-Haeuser, NatureSeal, Profile Food Ingredients | | Marine, wood finishes, powder coatings | PCG | Pettit, Woolsey, FinishWorks/Mohawk, TCI | | Residential DIY and professional painters | Consumer | Rust-Oleum, Zinsser, Varathane, DAP | | Household cleaning | Consumer | The Pink Stuff, Krud Kutter, Mean Green | | Pigments, colorants, OEM and personal care | Consumer (Color Group) | Day-Glo | | Restoration services equipment | CPG (Legend Brands) | Dri-Eaz, Sapphire Scientific | ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
Company Headquarters: Amsterdam, Netherlands Founded: 1994 Workforce: ~35,200 Company Working: Akzo Nobel N.V. operates its business by manufacturing products of various industries such as decorative paints, automotive & specialty coatings, industrial coatings, powder coating and marine, protective and yacht coatings. The automotive and specialty coatings segment of the business comprises products such as aerospace coatings, consumer electronics coatings, automotive OEM coatings, vehicle refinishes and sign finishes. Further, its industrial coatings segment offers products including coil and extrusion coatings, wood finishes, packaging coatings, and adhesives. The company owns more than 3,100 patents and has robust research and development capabilities which is evident from the fact that it has spent around USD 1.33 billion on research and development in last five years and possess five R&D centers. The brand portfolio offered by the company includes Dulux, Sikkens, International and Interpon and has a strong geographical presence in around 150 countries.
58 interactive charts drawn from the Bioresorbable Polymers Market dataset — market size, each segment breakdown, and every region and country by segment. Open one to read its full data table and download it.
Global Bioresorbable Polymers Market By Region
Global Bioresorbable Polymers Market By Polymer Type
Global Bioresorbable Polymers Market By Application
Global Bioresorbable Polymers Market — North America by Country
Global Bioresorbable Polymers Market — North America by Application
Global Bioresorbable Polymers Market — North America by Polymer Type
Global Bioresorbable Polymers Market — U.S. by Application
Global Bioresorbable Polymers Market — U.S. by Polymer Type
Global Bioresorbable Polymers Market — Canada by Application
Global Bioresorbable Polymers Market — Canada by Polymer Type
Global Bioresorbable Polymers Market — Mexico by Application
Global Bioresorbable Polymers Market — Mexico by Polymer Type
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and forecast (2022–2032, USD Million)
Market Size (USD Million)
